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Abstract
Objective: To estimate the risk for developing a defined neurodegenerative syndrome in a large cohort of idiopathic REM
sleep behavior disorder (IRBD) patients with long follow-up.
Methods: Using the Kaplan-Meier method, we estimated the disease-free survival rate from defined neurodegenerative
syndromes in all the consecutive IRBD patients diagnosed and followed-up in our tertiary referal sleep center between
November 1991 and July 2013.
Results: The cohort comprises 174 patients with a median age at diagnosis of IRBD of 69 years and a median follow-up of
four years. The risk of a defined neurodegenerative syndrome from the time of IRBD diagnosis was 33.1% at five years,
75.7% at ten years, and 90.9% at 14 years. The median conversion time was 7.5 years. Emerging diagnoses (37.4%) were
dementia with Lewy bodies (DLB) in 29 subjects, Parkinson disease (PD) in 22, multiple system atrophy (MSA) in two, and
mild cognitive impairment (MCI) in 12. In six cases, in whom postmortem was performed, neuropathological examination
disclosed neuronal loss and widespread Lewy-type pathology in the brain in each case.
Conclusions: In a large IRBD cohort diagnosed in a tertiary referal sleep center, prolonged follow-up indicated that the
majority of patients are eventually diagnosed with the synucleinopathies PD, DLB and less frequently MSA. IRBD
represented the prodromal period of these conditions. Our findings in IRBD have important implications in clinical practice,
in the investigation of the early pathological events occurring in the synucleinopathies, and for the design of interventions
with potential disease-modifying agents.
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Introduction
REM sleep behavior disorder (RBD) is a parasomnia charac-
terized by dream-enacting behaviors associated with REM sleep
without muscle atonia [1,2,3]. Longitudinal studies conducted in
sleep centers have shown that patients diagnosed with the
idiopathic form of RBD (IRBD) may eventually be diagnosed
with a neurological disorder such as Parkinson disease (PD) and
dementia with Lewy bodies (DLB) [4,5,6,7,8]. In a recent study we
assessed the first 44 IRBD individuals diagnosed in our tertiary
referral sleep center between 1991 and 2003 and found that after a
median follow-up of 10.5 years, 82% were diagnosed with PD,
DLB and less frequently multiple system atrophy (MSA) and mild
cognitive impairment (MCI). The estimated risk of defined
neurodegenerative syndrome from the diagnosis of IRBD was
34.8% at five years, 73.4% at ten years and 92.5% at 14 years [8].
These findings, in a group of 44 individuals with long and close
follow-up, indicate that most IRBD subjects develop a synucleino-
pathy with time. Since additional IRBD patients have been
diagnosed and followed-up in our sleep center, we aimed to
confirm our initial observation in a larger cohort of subjects that
comprises all the 174 consecutive IRBD cases diagnosed up to July
2013. Confirmation of our previous findings in a much larger
cohort would strongly support the notion that IRBD is a
manifestation of prodromal PD, DLB or MSA. This would carry
important implications in patient management, in understanding
the pathophysiology of the various disorders associated with
abnormal synuclein deposition, and could provide the opportunity
to test disease-modifying strategies before the onset of motor and
cognitive symptoms.
Methods
In the present study we determined the risk of development a
defined neurodegenerative syndrome in all the consecutive 174
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subjects that were diagnosed with IRBD between November 1991
and July 2013.
Patients’ Assessment
In all instances the diagnosis of IRBD required history of
dream-enacting behaviors, video-polysomnography detection of
REM sleep with increased muscular activity associated with
abnormal behaviors, absence of known neurodegenerative diseas-
es, lack of motor and cognitive complaints, normal neurological
examination, and RBD not explained by a brain lesion (e.g.,
stroke, demyelinating plaque, encephalitis) or by the introduction
or withdrawal of any medication or substance (e.g., antidepres-
sants, beta-blockers) [1,2,3].
The methods of clinical assessment at first and follow-up visits
have been described elsewhere [7,8]. In brief, patients were
referred to our sleep center where they or their bed partners
reported abnormal sleep behaviors. When the diagnosis of IRBD
was confirmed by video-polysomnography, patients underwent
routine follow-up visits every 3–12 months in our sleep center
where neurologists experienced in both sleep and neurodegener-
ative disorders assessed sleep quality. If during follow-up visits
neurologists, patients or relatives noted the appearance of
symptoms or signs suggestive of an emerging neurological
disorder, the patient was referred for detailed assessment to our
movement disorders or memory disorders units. Neurologists from
these units then formally assessed patients through detailed clinical
history, comprehensive neurological examination and neuropsy-
chological tests when cognitive impairment was suspected.
Diagnoses criteria applied were those accepted for PD, dementia,
DLB, MSA and MCI [9,10,11,12,13]. If patients were not able or
willing to attend our clinic, they were offered to undergo home
and home-nursing visits by a neurologist (A.I) and a neuropsy-
chologist (M.S) from our sleep center.
In the current study, to assess the presence and nature of a
defined neurodegenerative syndrome, clinical records were
reviewed, and all available patients were scheduled at our clinic
(or at their homes or nursing homes) between February and
August 2013. During these assessments, we conducted a detailed
medical history, a neurological examination and neuropsycholog-
ical testing when cognitive symptoms were first reported or
noticed. The clinical outcome of the patients (those who remained
with IRBD or those who were eventually diagnosed with a defined
neurodegenerative syndrome) was determined in all cases by
means of direct, face-to-face clinical interviews, neurological
examinations and neuropsychological tests. Diagnoses were not
done by telephone interviews. We also reviewed the neuropath-
ological findings (according to a protocol previously described [8])
of six patients from our cohort who died and donated their brain
to the Neurological Tissue Bank of the Biobank-Hospital Clinic de
Barcelona-IDIBAPS.
The study was approved by the Hospital Clinic of Barcelona
ethics committee and all participants or, when appropriate, their
relatives, gave written informed consent for clinical and post-
mortem neuropathological evaluations.
Statistical Analysis
Descriptive data are reported as median, mean, deviation
standard, number or percentage. Duration of RBD was defined as
the interval between the reported onset of RBD symptoms
(according to patients’ and bed partners’ estimation) and the time
of the last follow-up assessment or death. The date of IRBD
diagnosis was defined as the date when video-polysomnography
demonstrated REM sleep without atonia linked to abnormal
behaviors. Follow-up duration was defined as the interval from
diagnosis of IRBD to the time of the last visit or death. The onset
of a defined neurodegenerative syndrome (PD, DLB, MSA and
MCI) was determined as the date when the diagnosis was made
according to accepted clinical criteria. Duration of any emerging
defined neurodegenerative syndrome was defined as the interval
between the time of its diagnosis and the time of the last follow-up
assessment or death.
The risk of developing a defined neurodegenerative syndrome
in the 174 subjects from the cohort was estimated by means of the
Kaplan–Meier method.14 Disease-free survival rate was assessed
from the date of IRBD diagnosis to the date of the diagnosis of
defined neurodegenerative syndrome or to the last follow-up visit
for censored observations (subjects who died or were lost to follow-
up).
Demographic and clinical variables were compared between the
first 44 subjects reported previously [8] and the remaining 130
with Student’s t test and x2 test, as appropriate. The risk of
developing a neurodegenerative syndrome was calculated for the
two groups, and comparisons were assessed with the log rank test.
P values less than 0.05 were considered to be significant. All
analyses were done with SPSS version 20.0.
Results
In our sleep center, 174 individuals were diagnosed with IRBD
between November 1991 and July 2013. With the exceptions of
the duration of follow-up and the duration of RBD, there were no
demographic and clinical differences between the first 44 subjects
who were diagnosed between November 1991 and March 2003
and the remaining 130 who were diagnosed between April 2003
and July 2013 (Table 1).
Patients were 136 (78.2%) men and 38 (21.8%) women with a
median age at estimated RBD onset of 62.0 (range, 40 to 81) years,
median age at diagnosis of IRBD of 69.0 (range, 50 to 85) years,
and median interval between estimated RBD onset and IRBD
diagnosis of 4.0 (range, 0.5 to 30) years. The median age at last
visit was 74.0 (range, 57 to 91) years and the median follow-up
from IRBD diagnosis to the last visit or to death was 4.0 (range,
0.1 to 15) years.
By the 2013 assessment, 65 (37.4%) patients were diagnosed
with a defined neurodegenerative syndrome, 103 (59.2%)
remained disease-free, and 6 (3.4%) were lost to follow-up with
the diagnosis of IRBD at their last visit. Emerging diagnoses were
DLB in 29 subjects, PD in 22 (6 developed dementia after the
diagnosis of PD), MCI in 12 and MSA in two. These two subjects
were diagnosed with MSA of the cerebellar subtype based on the
presence of cerebellar signs plus dysautonomic features (e.g.,
orthostatic hypotension, urinary incontinence and erectile dys-
function). Follow-up visits disclosed the development of rigid-
akinetic parkinsonism unresponsive to levodopa in both, and
stridor due to bilateral vocal cord paralysis in one. None of our
IRBD patients were diagnosed with pure autonomic failure. In 25
of the 29 subjects who were diagnosed with DLB, a previous
period of MCI was recognized, and the median interval between
the diagnosis of MCI and DLB was 2.0 (range, 1 to 7) years. Two
patients with the diagnosis of MCI developed PD after two years,
and they have not developed dementia or visual hallucinations
after 2.4 and 3.1 years of follow-up.
In the 65 subjects diagnosed with a defined neurodegenerative
syndrome, the median interval between estimated RBD onset and
diagnosis of a defined neurodegenerative syndrome was 11.0
(range, 2 to 24) years, and the median interval between IRBD
diagnosis and diagnosis of a defined neurodegenerative syndrome
was 4.0 (range, 0.5 to 13) years. The risk of a defined
Neurodegeneration in Idiopathic RBD
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neurodegenerative syndrome from IRBD diagnosis was 33.1% at
five years, 75.7% at ten years, and 90.9% at 14 years (Figure 1).
The median conversion time in our sample was 7.560.5 years
(95% CI 6.5 to 8.4). No difference in the risk of developing a
neurodegenerative syndrome was found between the first 44
patients and the subsequent 130 patients (p = 0.319) (Figure 2).
During the follow-up period, 32 (18.4%) subjects were deceased.
Twenty-four of them were clinically diagnosed during life with a
defined neurodegenerative syndrome (11 with DLB, 10 with PD
and 3 with MCI), and the remaining eight had the diagnosis of
IRBD at their last follow-up visit. Six patients with the
antemortem diagnoses of DLB (n = 3), PD (n = 2, one of them
with associated dementia) and MCI (n = 1) were brain donors. In
two of them (the one with PD without dementia, and the one with
MCI) the peripheral autonomic nervous system was also available
for examination. In the brain, all six cases presented variable
neuronal loss, gliosis and alpha-synuclein immunoreactive Lewy
pathology (Lewy bodies and Lewy neurites) in vulnerable regions
such as the olfactory bulb, dorsal motor nucleus vagal nerve,
central raphe nucleus, the nuclei that regulate REM sleep muscle
atonia (gigantocellular reticular nucleus, pedunculopontine nucle-
us and coeruleus/subcoeruleus complex), substantia nigra pars
compacta, limbic structures (amygdala and anterior cingulate
cortex), and nucleus basalis of Meynert. Lewy pathology was also
detected in the neocortex of the three patients with the
antemortem diagnoses of DLB and of the PD patient who
developed dementia, corresponding in all of them to Lewy body
Braak stage 5 [15]. In the patient with the antemortem diagnosis
of PD who did not develop dementia and in the patient with MCI,
Lewy pathology was observed in the olfactory bulb, entire
brainstem and amygdala, preserving neocortical areas (Lewy body
Braak stage 4) [15]. In these two patients, a-synuclein aggregates
were observed in several regions of the peripheral autonomic
nervous system such as the paravertebral sympathetic chain,
epicardial fat tissue ganglia and myenteric plexus. As commonly
seen in patients with Lewy body disorders [16,17], concomitant
pathologies were observed and included 1) Alzheimer type
pathology in two of the donors with the clinical diagnosis of
DLB, 2) small vessel disease with microvascular lesions in two DLB
cases and the PD subject without dementia, and 3) argyrophilic
grain pathology in the PD patient with dementia, in one DLB case
and in the MCI case.
Discussion
This is the largest study with long term follow-up of IRBD. In a
cohort of 174 patients that were closely followed during a median
period of 4.0 years, survival curves showed that the estimated risk
of a defined neurodegenerative syndrome from the time of IRBD
diagnosis was 33.1% at five years, 75.7% at ten years, and 90.9%
at 14 years. Patients were clinically diagnosed with PD, DLB,
MSA and MCI. In patients who underwent postmortem brain
examination, the antemortem diagnoses of PD and DLB were
confirmed showing neuronal loss and widespread Lewy-type
pathology in selective brain regions. The patient with MCI and
lack of parkinsonism and dementia also had widespread Lewy type
pathology. The current study confirms our first observation [8]
that the majority of patients with IRBD that seek medical attention
are eventually diagnosed with a synucleinopathy. Ours is a
homogenous cohort where demographics, clinic characteristics
and survival curves are similar between the 44 subjects diagnosed
between 1991 and March 2003 [8] and the subsequent 130
subjects diagnosed between April 2003 and July 2013.
Similar results have been found by two other studies where
IRBD patients diagnosed in sleep tertiary centers were clinically
followed. The nature of disorders (synucleinopathies) evolving
from these two cohorts is very similar to what we have found in
our study. In the first study, Schenck et al. found that parkinson-
ism developed in 11 of 29 (38%) IRBD subjects nearly four years
after the diagnosis of IRBD and almost 13 years after the onset of
RBD [4]. After 16 additional years of follow-up, 21 (72.4%) IRBD
Table 1. Comparison between the first 44 subjects who were diagnosed with IRBD between November 1991 and March 2003, and
the following 130 who were diagnosed between April 2003 and July 2013.
Patients diagnosed with IRBD
between November 1991 and
March 2003 (n = 44)
Patients diagnosed with IRBD
between April 2003 and
July 2013 (n = 130) P value
Sex (male/female) 39/5 97/33 0.052
Age at estimated RBD onset (years) 62.7567.34 (45–77) 62.3267.92 (40–81) 0.744
Age at RBD diagnosis (years) 69.0766.56 (56–85) 68.5766.32 (50–85) 0.655
RBD duration (years) 16.5065.07 (8–31) 10.1666.65 (1–34) ,0.0001
Follow-up duration after diagnosis
of RBD (years)
9.6463.34 (1–15) 3.5062.72 (0.1–10) ,0.0001
Self-awareness of abnormal sleep behaviors 28(63.6%) 70(54.3%) 0.279
Unpleasant dream recall 42(95.5%) 118(90.8%) 0.323
Age at diagnosis of emerging defined
neurodegenerative syndrome (years)
74.6465.60 (60–85) 74.3164.13 (64–80) 0.793
Diagnoses of emerging defined
neurodegenerative syndrome (n)
PD= 16 DLB = 15 MSA= 1 MCI = 4 PD= 6 DLB = 14 MSA=1 MCI = 8
Estimated risk of conversion after
5 years of IRBD diagnosis (%)
34.8 22.6
Estimated risk of conversion after
10 years of IRBD diagnosis (%)
73.4 72.2
Data are given in number, mean, standard deviation and range. RBD= REM sleep behavior disorder; PD= Parkinson disease; DLB = dementia with Lewy bodies;
MSA=multiple system atrophy; MCI =mild cognitive impairment.
doi:10.1371/journal.pone.0089741.t001
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patients from the original cohort where diagnosed with PD in 13
cases, DLB in three, MSA in two, unspecified dementia in one,
and Alzheimer’s disease with autopsy-confirmed combined
Alzheimer’s disease pathology plus Lewy pathology in two. Three
IRBD subjects were lost during the follow-up period [5]. In this
study, the presence of MCI was not evaluated and the risk of
disease was not examined using survival curves and statistical
analysis. In a second series, Postuma et al. found that 26 of 93
(28%) IRBD patients developed a neurodegenerative disorder
after a mean follow-up of five years; PD in 14, DLB in seven,
dementia that met clinical criteria for Alzheimer’s disease (but also
for possible DLB) in four, and MSA in one. Survival curves
showed that the estimated risk of a neurodegenerative disease after
RBD diagnosis was 17.7% at five years, 40.6% at 10 years, and
52.4% at 12 years [6]. When compared with our study, the lower
conversion rate and the lower estimated risk of developing
neurodegenerative disease found by Postuma et al. may be
explained by methodological aspects. In the study by Postuma
et al. the design was retrospective (while ours was prospective), the
status of 15 patients was assessed through telephone interviews
(while all of our patients were assessed by in-person examinations
even examining them at their homes and nursing-homes), 20
(17.7%) of their initial 113 patients where lost during the follow-up
(while we lost only six 23.4%2 of 174 subjects), neuropathologic
confirmation of a disease was not provided (in our study this was
done in six subjects), the mean age at the time of the study was 65
years (while in ours it was 74 years), and MCI was not considered
as a disease outcome.
Our findings indicate that there is a strong and specific
association of IRBD with PD and DLB, and that this parasomnia
can be considered in most cases a prodromal manifestation. In PD,
other clinical features known to precede the motor symptoms such
as hyposmia, constipation, depression and hypersomnia are much
less specific since only a small number of individuals with these
symptoms are eventually diagnosed with PD [18,19]. This
positions IRBD as an optimal target population to study the
prodromal stage of the synucleinopathies and eventually to test
disease-modifying strategies in these disorders before motor and
cognitive changes have developed.
The findings of our study have clinical relevance and research
implications. The investigation of patients with IRBD offers a
unique opportunity to obtain information of the aetiology,
pathogenesis and progression of the prodromal stage of the
synucleinopathies. In IRBD, clinical, neuroimaging, biochemical,
proteomic and genetic studies will help to better understand the
mechanisms of neurodegeneration and to design interventions
Figure 1. Rates of neurological-disease-free-survival according to the time of IRBD diagnosis in the 174 patients from the cohort.
doi:10.1371/journal.pone.0089741.g001
Neurodegeneration in Idiopathic RBD
PLOS ONE | www.plosone.org 4 February 2014 | Volume 9 | Issue 2 | e89741
with potential disease modifying properties. To date, several
studies have added weight to the concept that IRBD represents in
most cases an evolving synucleinopathy in its earliest phases.
Several studies have found that IRBD patients display clinical (e.g.,
hyposmia [20], depression [21], autonomic dysfunction [21]) and
neuroimaging (e.g., decreased dopamine transporter binding in
the striatum [22], substantia nigra hypechogenicity [22], increased
mean diffusivity in the pons [23]) abnormalities which are
characteristic features of the synucleinopathies. Overall, these
studies suggest that at the time IRBD is diagnosed a neurodegen-
erative process is already widespread in the nervous system. Of
these abnormalities, the combination of hyposmia with colour
vision impairment [20], and the combination of substantia nigra
hyperechogenicity with decreased striatal dopamine transporter
uptake [21] may identify those IRBD patients who are at increased
short-term risk for being diagnosed with a synucleinopathy
according to accepted clinical criteria. Prospective studies have
further shown that while colour vision and olfactory dysfunction
[20,24] remains stable over time, dopamine transporter imaging
shows progressive decline in striatal tracer uptake [25]. Thus,
dopamine transporter imaging, and not olfactory and colour vision
functions, serve better as a marker of progression in IRBD.
The finding that IRBD patients are later frequently diagnosed
with DLB and PD with associated dementia suggests that both
disorders may represent different phenotypes from the same
condition. MCI is an intermediate stage between normal cognitive
function and dementia where individuals have cognitive com-
plaints, deficits in neuropsychological tests and their daily living
activities are preserved [13]. In our study MCI was considered a
disease outcome. This is because in the particular setting of IRBD,
MCI can be considered an abnormal condition which frequently
evolves into DLB and PD. This is based on the following data.
First, MCI occurs in nearly 20% of untreated PD patients at the
time of initial diagnosis [26], and predicts conversion to dementia
[27]. Of note, two our MCI patients have developed parkinsonism
but not dementia or hallucinations to date. Second, most IRBD
patients seen in sleep centers who develop MCI are eventually
diagnosed with DLB [8]. Third, IRBD patients that develop MCI
but no dementia show markers of a synucleinopathy such as
decreased striatal dopamine transporter, hyperechogenicity of the
substantia nigra and hyposmia [8]. Fourth, in patients with MCI
with comorbid RBD who later develop dementia, postmortem
examination shows Lewy-body pathology [28]. Finally, in a
population-based study involving 651 individuals, RBD conferred
a 2.2-fold increased risk of developing MCI over a 4-year period of
observation [29]. The above data is supported by our current
observation in one patient who developed MCI (and not dementia
or parkinsonism) and neuropathology demonstrated neuronal loss
Figure 2. Rates of neurological-disease-free-survival according to the time of IRBD diagnosis in the first 44 patients from the cohort
(doted line) and the remaining 130 (continuous line).
doi:10.1371/journal.pone.0089741.g002
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and widespread alpha-synuclein related Lewy body pathology
involving the peripheral nervous system, olfactory bulb, entire
brainstem (including the substantia nigra) and the limbic system.
Limitations of our study should be acknowledged. Our study did
not include a control group of healthy subjects without RBD who
were followed-up on during a similar time period. In the present
study, the proportion of IRBD subjects that developed a
neurological condition was 37% over a median follow-up period
of 4 years. This proportion is greatly superior to the estimated
prevalence of these neurological disorders in a population of
individuals of similar age and sex distribution [30,31,32,33]. Our
cohort comprises patients who were self-referred to a tertiary sleep
center. It is uncertain if our observations can be generalized to the
individuals with IRBD in the general population that do not seek
medical attention. Strenghts of our study include confirmation of
RBD by polysomnography in all cases, a large number of study
subjects, and a long and close follow-up (which included home and
home-nursing visits when needed) reflected by a low number (3%)
of patients who were lost. In addition, pathological confirmation
was available in six cases and clinical outcome (disease free or
diagnosed with a defined neurodegenerative syndrome) was in all
cases determined by in-person assessment through clinical history
and neurological evaluation.
In summary, our study shows that a majority of IRBD patients
with prolonged follow-up are diagnosed with the synucleinopathies
PD, DLB and MSA. IRBD represents the prodromal period of
these conditions. Our findings in IRBD have important implica-
tions in clinical practice, in the investigation of the early
pathological events occurring in the synucleinopathies, and for
the design of future trials with potential disease-modifying agents.
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